Towards a European personalized registry for colorectal cancer patients: 919 patients have already enrolled!

About the project Download the brochure

What's New?

Ignyta and EORTC Announce Entrectinib as 1st Investigational Cancer Agent in EORTC SPECTA

in Media, Press Releases

research-2

SAN DIEGO and BRUSSELS–(BUSINESS WIRE)–Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, and the European Organisation for Research and Treatment of Cancer (EORTC) today announced that they will collaborate via EORTC’s Screening Patients for Efficient Clinical Trial Access (SPECTA) biomarker screening initiative to identify patients who harbor a gene rearrangement to NTRK1, NTRK3, ROS1… Read more »

14M Genomics and EORTC and Announce First Results from their Collaboration on Tumour Profiling

in Media, Press Releases, Science

14mg

Cambridge, UK: 16 November 2015.  14M Genomics (“14MG”) and The European Organisation for Research and Treatment of Cancer (“EORTC”) today announce the delivery of initial genomic mutation analyses conducted on newly diagnosed cancer patients as part of the EORTC Screening Patients for Efficient Clinical Trial Access (SPECTA) programme. The first SPECTA project, SPECTAcolor, focuses on… Read more »

SPECTAcolor bi-annual Investigators’ meeting, 22 October 2015, Antwerp, Belgium

in Consortium, Media, Meetings, Science

Capture.Anvers. small

On 22 October 2015, the SPECTAcolor project investigators met up at the occasion of the bi-annual series of SPECTAcolor Steering Committee meetings to discuss the Biobank project progress. This private meeting was held concurrently with the EORTC GITCG semi annual meeting in Antwerp, Belgium. View the agenda of the investigators’ meeting for information.    … Read more »

839 patients enrolled since the opening of the biobank in September 2013!

in Consortium, Media, Science

canstock10069339

SPECTAcolor is the first ever tumour tissue samples biobank and biomarker analysis platform for genetic profiling of patients suffering from advanced colorectal cancer. This platform, unique of its kind joins up research clinical forces at a Pan-European level to develop personalized treatments based on the results of the tissue sampling analysis. Supported by a network of over… Read more »

The Catalan Institute of Oncology welcomes delegates from Walgreens Boots Alliance

in Media

barcelona

      Barcelona – The Catalan Institute of Oncology (ICO) today welcomed a party of over 35 delegates from Walgreens Boots Alliance, the first global pharmacy-led health and wellbeing enterprise to showcase the workings of the Screening Patients for Efficient Clinical Trial Access (SPECTAcolor) Biobank of the European Organisation for Research and Treatment of Cancer (EORTC)… Read more »

SPECTAcolor viable next generation multinational cancer clinical trial infrastructure

in Media, Press Releases

dresden

Over 500 patients in and availability of high quality biological materials SPECTAcolor’s successful start has demonstrated its viability to facilitate next generation cancer clinical trials. It has been successfully implemented across 21 clinical centers located in nine countries in Europe, has now recruited over 500 patients since its launch in September 2013, and the observed frequency… Read more »

2nd SPECTAcolor bi-annual Investigators’ meeting, 19 November 2014, Stockholm

in Consortium, Media, Meetings

Stockholm

On 19 November 2014, the SPECTAcolor project investigators and partners met up at the occasion of the 2nd  of the bi-annual series of SPECTAcolor Steering Committee Meetings to discuss the biobank project progress. View the agenda of the investigators’ meeting for information. This private meeting is to be traditionally held concurrently at the occasion of the GI Oncology Study… Read more »

1 year in, SPECTAcolor is a viable cancer research model!

in Media

Gunnar-Folprecht-featured-image

The EORTC is pleased to announce the successful implementation of SPECTAcolor, ‘Screening Patients for Efficient Clinical Trial Access’ – the first Pan European collaborative molecular screening platform for colorectal cancer patients. SPECTAcolor proves the logistical feasibility of the infrastructure that was built to run next generation trials in a multinational setting. Now one year into… Read more »